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COMMENTARY Open Access
Inflammatory Wnt5A signalling pathways
affecting barrier function of human
vascular endothelial cells
Tom Skaria and Gabriele Schoedon*
Abstract
Wnt5A is a chemokine secreted by inflammatory-activated human macrophages that sustains their inflammatory
response in an autocrine manner. High levels of Wnt5A are found in sera of patients with sepsis and septic shock.
Here, we comment on recently reported Wnt5A signalling pathways in human vascular endothelial cells (VEC). In
human VEC, Wnt5A regulates cytoskeleton remodelling and barrier function through Ryk receptor and Rho-associated
protein serine/threonine kinase, targeting LIMK2 and CFL1 involved in actin polymerisation. Wnt5A/Ryk signalling in
VEC can be antagonised by the naturally occurring Wnt inhibitory factor (WIF)-1 (WIF1).
Therapeutic targeting of this mechanism may reduce vascular leakage and edema in severe systemic inflammation and
therefore should be subject of further investigations.
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Vascular leakage caused by endothelial barrier dysfunction
is a critical feature of severe systemic inflammatory
diseases like sepsis, or allergic responses and autoimmune
disorders. Wnt5A has been identified as a chemokine
secreted by Toll-like receptor (TLR)-activated human
macrophages that is crucially involved in the autocrine
modulation of their inflammatory response [1, 2]. Here,
we comment on the novel finding of a Wnt5A/Ryk signal-
ling mechanism regulating cytoskeleton remodelling and
barrier function in adult human immunocompetent
vascular endothelial cells (VEC).
In our recent study employing differential gene expres-
sion profiling of VEC treated with the potent Th2
cytokine IL-4, Wnt5A was surprisingly found among the
top upregulated genes [3]. The top most significant
pathways regulated by IL-4 in VEC were those contain-
ing genes associated with cytoskeleton remodelling, for
which Wnt5A might be a potential ligand. The genes
clustered in these pathways were LIMK2, a serine/threo-
nine/tyrosine kinase phosphorylated by the activation of
Rho-associated protein serine/threonine kinase (ROCK),
and the actin depolymerization factor CFL1 [3]. A separate
study employing whole genome transcriptome profiling of
paracrine Wnt5A treatment in primary VEC verified that
the same cytoskeleton remodelling pathway involving
LIMK2 and CFL1 is the cellular process most significantly
regulated by Wnt5A in VEC [4]. Phosphorylated LIMK2
phosphorylates, and thereby inactivates CFL1 leading to
enhanced actin polymerization. In response to IL-4 and
Wnt5A treatments, LIMK2 and CFL1 were phosphory-
lated, and actin stress fiber formation was enhanced [3, 4].
A crucial involvement of autocrine Wnt5A in IL-4 induced
cytoskeleton remodelling process was revealed by the find-
ing that actin stress fiber formation in IL-4-treated VEC
was notably decreased in the presence of the Ryk receptor
specific Wnt antagonist, Wnt inhibitory factor (WIF)-1
(WIF1). Barrier dysfunction of IL-4- treated VEC mono-
layers was found significantly suppressed by silencing
Wnt5A [3]. Likewise, silencing Ryk expression prevented
Wnt5A-mediated endothelial barrier dysfunction [4]. It
has been further shown that WIF1 specifically prevents
Wnt5A-mediated LIMK2/CFL1 phosphorylation and
adherens junction disruption [5]. Collectively, these data
reveal that the Wnt5A/Ryk pathway regulates actin
cytoskeleton remodelling and monolayer barrier function
of human VEC through ROCK/LIMK/CFL signalling. The
transcription factors and the molecular mechanism
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mediating Wnt5A induction in response to IL-4 treatment
in VEC still remain unclear and warrant further studies.
Importantly, it was further shown that Wnt5A does
not regulate the expression of proinflammatory cyto-
kines or intercellular adhesion molecules in human VEC
[4], in contrast to the Frizzled (Fzd)-5 receptor mediated
Wnt5A signalling in macrophages [1, 2]. Wnt5A can
trigger multiple signalling pathways depending on the
cellular milieu, the availability of receptors, and naturally
occurring Wnt antagonists [6]. Therefore, the ability of
Wnt5A to engage two distinct receptors and signalling
pathways in macrophages and VEC is not surprising.
Taken together, recent studies mentioned [3–5] strongly
indicate that Wnt5A/Ryk signalling mediates cytoskeleton
remodelling and barrier dysfunction in human VEC, and
these processes are critically modulated by the endogen-
ous protein WIF1 [5]. Previous studies report elevated
levels of Wnt5A in sera of patients with severe sepsis and
septic shock [2], that is corroborated by the finding of
strongly induced synthesis and secretion of Wnt5A by
TLR-activated macrophages. This along with the present
finding of highly induced Wnt5A expression in IL-4-
activated VEC prompt further studies to investigate if
Wnt5A contributes to vascular leakage and edema forma-
tion in severe systemic inflammatory diseases like sepsis/
septic shock, and in IL-4 driven allergic inflammation.
Investigations are also needed to unravel the intriguing
finding of Wnt5A being induced by two different inflam-
matory pathways that are evolutionary highly conserved,
TLR-dependent and IL-4 dependent signalling. Targeting
paracrine, as well as autocrine Wnt5A signalling by WIF1
may open novel therapeutic perspectives for the treatment
of capillary leakage in systemic inflammatory conditions
such as severe inflammation and sepsis, as well as allergic
and autoimmune diseases.
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